hxdbzxy Foghorn Therapeutics ( NASDAQ: FHTX ) priced a $110M mixed-shelf registered direct offering of its shares and prefunded warrants. The company said it plans to offer 12.7M of its common shares priced at $5.
51 per share. In lieu of common stock for certain investors, prefunded warrants to buy up to 7.2M common shares were priced at $5.
5099 per pre-funded warrant. The transaction is expected to close around May 22 and generate gross proceeds of $110M. Jefferies, TD Cowen and Evercore ISI are serving as joint bookrunners on the deal.
More on Foghorn Therapeutics Foghorn Therapeutics appoints Kristian Humer as chief financial officer Seeking Alpha’s Quant Rating on Foghorn Therapeutics Historical earnings data for Foghorn Therapeutics Financial information for Foghorn Therapeutics.
